 Blood clotting and thrombosis have been associated with drug coated heart stents such as Johnson & Johnson's Cypher Stent. It is believed that these health concerns are four to five times more likely than with regular metal stents, according to a Cleveland Clinic study released November 29, 2006. Patients with drug coated stents should contact attorney at the Singleton Law Firm today to for a free case evaluation.
Late thrombosis associated with stents following angioplasty can lead to heart attacks, stroke and death. The Cypher stent was originally approved by the FDA in early 2003 and emits the drug Sirolimus, which is intended to solve the restenosis (reclosure) problem by slowing the overgrowth of the endothelial cells in the blood vessels. Some health care professionals believe that Sirolimus slows the creation of a protective coating that grows in the vessel around the stent to protect against clots.
The Cypher Stent was approved by the FDA for angioplasty procedures to open clogged coronary arteries. In most cases, a stent is left permanently in the artery to keep the vessel open after angioplasty. The Cypher stent is designed to slowly release a drug which helps to reduce the rate of re-blockage that occurs. The FDA warned that Johnson & Johnson's newest heart device, the drug coated Cypher Stent, has been linked to hundreds of cases of blood clots and said the device has been linked to more than 60 deaths. This warning was the second warning sent to doctors since the launch of the Cypher stent in April 2003.
The symptoms associated with the stent include pain, rash, respiratory alterations, hives, itching, fever, blood pressure changes and in some instances death.
If you or a loved one suffered injuries from a Johnson & Johnson Cypher stent, please contact the attorneys at the Singleton Law Firm for an immediate case evaluation today.
Return to the Defective Drugs Listing > |
